Dopaminergic Agonists with Iron-Binding Catechol Moieties for Parkinson's Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacotherapeutic agents for Parkinson's disease, particularly those targeting dopaminergic receptor systems, face challenges in selectively binding to D2 and D3 receptors due to their shared agonist binding sites and distribution patterns, leading to oxidative stress and side effects, necessitating improved D2/D3 agonist molecules that can bind to iron.
Innovation Solution
Development of compounds with specific formulas (I and II) that include various substituents and linking moieties, allowing for selective binding to D2 and D3 receptors, potentially reducing oxidative stress and improving treatment efficacy by inhibiting alpha-synuclein fibrillization and amyloid beta aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional dopaminergic receptor agonists are used to treat Parkinson's disease, then motor symptoms can be relieved, but selective binding to D2 and D3 receptors is compromised leading to oxidative stress and side effects
Solution Approach 1:
The patent applies local quality by introducing specific functional groups (catechol moiety with iron-binding capability) at particular positions of the dopaminergic agonist molecule. This localized modification enables selective binding to D2/D3 receptors while avoiding non-specific interactions that cause oxidative stress, thus resolving the contradiction between reliability and harmful effects.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of conventional dopaminergic agonists through specific substitutions (Formula I and II structures with iron-binding catechol groups). These structural parameter changes enhance receptor selectivity and reduce oxidative stress, simultaneously improving reliability while reducing harmful factors.
2Reliability
If D2 and D3 receptor agonists are developed to improve selectivity, then receptor binding specificity can be enhanced, but the complexity of achieving subtype selectivity increases due to shared binding sites
Solution Approach 1:
The patent applies segmentation by dividing the dopaminergic agonist molecule into distinct functional segments: a core dopaminergic pharmacophore for receptor engagement and a catechol moiety with iron-binding capability for selective D2/D3 interaction. This segmented structure achieves binding specificity without excessive molecular complexity.
Solution Approach 2:
The patent employs composite materials by creating hybrid molecules that combine dopaminergic agonist structures with iron-binding catechol groups (Formula I and II). This composite approach integrates multiple functions into a single molecule, enhancing receptor specificity while maintaining manageable structural complexity.
Data Source
AI summary
A compound having formula I is useful for treating a neurodegenerative disease:or a pharmaceutically acceptable salt or ester thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8 are each independently hydroxyl, C1-4 alkyl, C1-4 alkoxyl, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C4-8, are specified substituents.